
Innovent and Spero Ink $1.1 Billion Licensing Deal for IBI355
Spero Therapeutics has secured exclusive global rights, excluding Greater China, to develop and commercialize IBI355, a third-generation anti-CD40L antibody developed by Innovent Biologics. The deal, valued at approximately $1.1 billion in milestone payments and royalties, marks a significant expansion of Spero’s immunology pipeline into chronic fibroinflammatory conditions.







&format=webp)


















